CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease

Expert Review of Respiratory Medicine

Volumn 12, Issue 6, 2018, Pages 483-492

  Fernandez Fernandez, Elena ^a   De Santi, Chiara ^a   De Rose, Virginia ^b   Greene, Catherine M ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

chronic obstructive pulmonary disease (COPD); cystic fibrosis (CF); Cystic fibrosis transmembrane conductance regulator (CFTR)

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR PROTEIN, HUMAN; MESSENGER RNA;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MUTATION;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MUTATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 85047997740     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1080/17476348.2018.1475235     Document Type: Review

References (108)

1. Zielenski J, Bozon D, Kerem B, et al. Identification of mutations in exons 1 through 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics. 1991;10:229–235.
2. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science (80-). 1989;245:1059–1065.
3. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science (80-). 1989;245:1066–1073.
4. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science (80-). 1989;245:1073–1080.
5. Cheng SH, Rich DP, Marshall J, et al. Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell. 1991;66:1027–1036.
6. Ko SBH, Zeng W, Dorwart MR, et al. Gating of CFTR by the STAS domain of SLC26 transporters. Nat Cell Biol. 2004;6:343–350.
7. Welsh MJ, Smith AE., Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73:1251–1254.
8. Poulsen JH, Fischer H, Illek B, et al. Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci U S A. 1994;91:5340–5344.
9. Kogan I, Ramjeesingh M, Li C, et al. CFTR directly mediates nucleotide-regulated glutathione flux. Embo J. 2003;22:1981–1989.
10. Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science (80-). 1995;269:847–850.
11. Mall M, Grubb BR, Harkema JR, et al. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med. 2004;10:487–493.
12. Wang X, Matteson J, An Y, et al. COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses di-acidic exit code. J Cell Biol. 2004;167:65–74.
13. Skach WR., Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulator. Kidney Int. 2000;57:825–831.
14. Farinha CM, Matos P, Amaral MD. Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi. Febs J. 2013;280:4396–4406.
15. Prince LS, Peter K, Hatton SR, et al. Efficient endocytosis of the cystic fibrosis transmembrane conductance regulator requires a tyrosine-based signal. J Biol Chem. 1999;274:3602–3609.
16. Sharma M, Pampinella F, Nemes C, et al. Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J Cell Biol. 2004;164:923–933.
17. Cantin AM, Hartl D, Konstan MW, et al. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros. 2015;14:1–12.
18. Elborn JS. Cystic fibrosis. Lancet. 2016;388:2519–2531.
19. Andersen DH. Cystic Fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child. 1938;56:344.
20. Mehta G, Macek M, Mehta A. Cystic fibrosis across Europe: euroCareCF analysis of demographic data from 35 countries. J Cyst Fibros. 2010;9:S5–S21.
21. Cystic Fibrosis Foundation. Cystic fibrosis foundation patient registry 2012 annual data report. 2012. p. 28.
22. Quon BS, Rowe SM. New and emerging targeted therapies for cystic fibrosis. Bmj. 2016;352:i859.
23. De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. Lancet Respir Med. 2016;4:662–674.
24. McNally P, Greene CM. Cystic fibrosis: a model for precision medicine. Expert Rev Precision Med Drug Dev. 2018;2:107–117.
25. Mall MA, Hartl D. CFTR: cystic fibrosis and beyond. Eur Respir J. 2014;44:1042–1054.
26. Birket SE, Chu KK, Liu L, et al. A functional anatomic defect of the cystic fibrosis airway. Am J Respir Crit Care Med. 2014;190:421–432.
27. Tang XX, Ostedgaard LS, Hoegger MJ, et al. Acidic pH increases airway surface liquid viscosity in cystic fibrosis. J Clin Invest. 2016;126:879–891.
28. Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature. 2012;487:109–113.
29. Hartl D, Gaggar A, Bruscia E, et al. Innate immunity in cystic fibrosis lung disease. J Cyst Fibros. 2012;11:363–382.
30. Cantin AM, Hartl D, Konstan MW, et al. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros. 2015;14:419–430.
31. De Rose V. Mechanisms and markers of airway inflammation in cystic fibrosis. Eur Respir J. 2002;19:333–340.
32. Cohen-Cymberknoh M, Kerem E, Ferkol T, et al. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax. 2013;68:1157–1162.
33. Cystic fibrosis mutation database: statistics [Internet]. [cited 2017 Aug9]. Available from: http://www.genet.sickkids.on.ca/cftr/StatisticsPage.html
34. Protasevich I, Yang Z, Wang C, et al. Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide-binding domain 1. Protein Sci. 2010;19:1917–1931.
35. Delaney SJ, Alton EW, Smith SN, et al. Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations. Embo J. 1996;15:955–963.
36. Sheppard DN, Rich DP, Ostedgaard LS, et al. Mutations in CFTR associated with mild-disease-form Cl- channels with altered pore properties. Nature. 1993;362:160–164.
37. Ramalho AS, Beck S, Meyer M, et al. Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am Respir Cell Mol Biol. 2002;27:619–627.
38. Taulan M, Lopez E, Guittard C, et al. First functional polymorphism in CFTR promoter that results in decreased transcriptional activity and Sp1/USF binding. Biochem Res Commun. 2007;361:775–781.
39. Haardt M, Benharouga M, Lechardeur D, et al. C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J Biol Chem. 1999;274:21873–21877.
40. Viart V, Bergougnoux A, Bonini J, et al. Transcription factors and miRNAs that regulate fetal to adult CFTR expression change are new targets for cystic fibrosis. Eur Respir J. 2015;45:116–128.
41. Oglesby IK, Chotirmall SH, McElvaney NG, et al. Regulation of cystic fibrosis transmembrane conductance regulator by MicroRNA-145, −223, and −494 is altered in ΔF508 cystic fibrosis airway epithelium. J Immunol. 2013;190:3354–3362.
42. Ramachandran S, Karp PH, Osterhaus SR, et al. Post-transcriptional regulation of cystic fibrosis transmembrane conductance regulator expression and function by microRNAs. Am J Respir Cell Mol Biol. 2013;49:544–551.
43. Oglesby IK, Bray IM, Chotirmall SH, et al. miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. J Immunol. 2010;184:1702–1709.
44. Gillen AE, Gosalia N, Leir S-H, et al. MicroRNA regulation of expression of the cystic fibrosis transmembrane conductance regulator gene. Biochem J. 2011;438:25–32.
45. Megiorni F, Cialfi S, Dominici C, et al. Synergistic post-transcriptional regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) by miR-101 and miR-494 specific binding. Schrijver I, editor. PLoS One. 2011;6:e26601.
46. Amato F, Seia M, Giordano S, et al. Gene mutation in MicroRNA target sites of CFTR gene: a novel pathogenetic mechanism in cystic fibrosis? Vij N, editor. PLoS One. 2013;8:e60448.
47. Amato F, Tomaiuolo R, Nici F, et al. Exploitation of a very small peptide nucleic acid as a new inhibitor of miR-509-3p involved in the regulation of cystic fibrosis disease-gene expression. Biomed Res Int. 2014;2014:610718.
48. Ramachandran S, Karp PH, Jiang P, et al. A microRNA network regulates expression and biosynthesis of wild-type and DeltaF508 mutant cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci U S A. 2012;109:13362–13367.
49. Kumar P, Bhattacharyya S, Peters KW, et al. miR-16 rescues F508del-CFTR function in native cystic fibrosis epithelial cells. Gene Ther. 2015;22:908–916.
50. Hassan T, McKiernan PJ, McElvaney NG, et al. Therapeutic modulation of miRNA for the treatment of proinflammatory lung diseases. Expert Rev Anti Infect Ther. 2012;10:359–368.
51. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:347–365.
52. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128.
53. López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21:14–23.
54. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765–773.
55. COPD, Awareness Month, NHLBI, NIH [Internet]. [cited 2017 Aug2]. Available from: https://www.nhlbi.nih.gov/health/educational/copd/event-listing/awareness-month/materials-resources.htm
56. Ni I, Ji C, Vij N. Second-Hand Cigarette Smoke Impairs Bacterial Phagocytosis in Macrophages by Modulating CFTR Dependent Lipid-Rafts. Chu HW, editor. PLoS One. 2015;10:e0121200.
57. WHO | Causes of COPD. WHO; 2013.
58. Rab A, Rowe SM, Raju SV, et al. Cigarette smoke and CFTR: implications in the pathogenesis of COPD. Am J Physiol Lung Cell Mol Physiol. 2013;305:L530–L541.
59. Cantin AM. Cystic fibrosis transmembrane conductance regulator. implications in cystic fibrosis and chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016;13:S150–S155.
60. Raju SV, Lin VY, Liu L, et al. The cystic fibrosis transmembrane conductance regulator potentiator ivacaftor augments mucociliary clearance abrogating cystic fibrosis transmembrane conductance regulator inhibition by cigarette smoke. Am J Respir Cell Mol Biol. 2017;56:99–108.
61. Welsh MJ. Cigarette smoke inhibition of ion transport in canine tracheal epithelium. J Clin Invest. 1983;71:1614–1623.
62. Cantin AM, Hanrahan JW, Bilodeau G, et al. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med. 2006;173:1139–1144.
63. Dransfield MT, Wilhelm AM, Flanagan B, et al. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. Chest. 2013;144:498–506.
64. Kreindler JL, Jackson AD, Kemp PA, et al. Inhibition of chloride secretion in human bronchial epithelial cells by cigarette smoke extract. AJP Lung Cell Mol Physiol. 2005;288:L894–L902.
65. Clunes LA, Davies CM, Coakley RD, et al. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. Faseb J. 2012;26:533–545.
66. Sloane PA, Shastry S, Wilhelm A, et al. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. Kreindler JL, editor. PLoS One. 2012;7:e39809.
67. Innes AL, Woodruff PG, Ferrando RE, et al. Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest. 2006;130:1102–1108.
68. Mall MA. Unplugging mucus in cystic fibrosis and chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016;13:S177–S185.
69. 2+ release Leads to Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) dysfunction. J Biol Chem. 2014;289:7671–7681.
70. Johannesson B, Hirtz S, Schatterny J, et al. CFTR regulates early pathogenesis of chronic obstructive lung disease in βENaC-overexpressing mice. Vij N, editor. PLoS One. 2012;7:e44059.
71. Ghosh A, Boucher RC, Tarran R. Airway hydration and COPD. Cell Mol Life Sci. 2015;72:3637–3652.
72. Button B, Anderson WH, Boucher RC. Mucus hyperconcentration as a unifying aspect of the chronic bronchitic phenotype. Ann Am Thorac Soc. 2016;13(Suppl 2):S156–S162.
73. Ballard ST, Trout L, Bebök Z, et al. CFTR involvement in chloride, bicarbonate, and liquid secretion by airway submucosal glands. Am J Physiol. 1999;277:L694–L699.
74. Hug MJ, Tamada T, Bridges RJ. CFTR and bicarbonate secretion to epithelial cells. Physiology. 2003;18:38–42.
75. Bodas M, Min T, Vij N. Critical role of CFTR-dependent lipid rafts in cigarette smoke-induced lung epithelial injury. Am J Physiol Lung Cell Mol Physiol. 2011;300:L811–L820.
76. Raju SV, Jackson PL, Courville CA, et al. Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. Am J Respir Crit Care Med. 2013;188:1321–1330.
77. Rennolds J, Butler S, Maloney K, et al. Cadmium regulates the expression of the cftr chloride channel in human airway epithelial cells. Toxicol Sci. 2010;116:349–358.
78. Hassan F, Nuovo GJ, Crawford M, et al. MiR-101 and miR-144 regulate the expression of the CFTR chloride channel in the lung. Kreindler JL, editor. PLoS One. 2012;7:e50837.
79. Hassan F, Xu X, Nuovo G, et al. Accumulation of metals in GOLD4 COPD lungs is associated with decreased CFTR levels. Respir Res. 2014;15:69.
80. Le Gars M, Descamps D, Roussel D, et al. Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. Am J Respir Crit Care Med. 2013;187:170–179.
81. Alexander NS, Blount A, Zhang S, et al. Cystic fibrosis transmembrane conductance regulator modulation by the tobacco smoke toxin acrolein. Laryngoscope. 2012;122:1193–1197.
82. Moran AR, Norimatsu Y, Dawson DC, et al. Aqueous cigarette smoke extract induces a voltage-dependent inhibition of CFTR expressed in Xenopus oocytes. AJP Lung Cell Mol Physiol. 2014;306:L284–L291.
83. Gao L, Kim KJ, Yankaskas JR, et al. Abnormal glutathione transport in cystic fibrosis airway epithelia. Am J Physiol. 1999;277:L113–L118.
84. Church DF, Pryor WA. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect. 1985;64:111–126.
85. René C, Lopez E, Claustres M, et al. NF-E2-related factor 2, a key inducer of antioxidant defenses, negatively regulates the CFTR transcription. Cell Mol Life Sci. 2010;67:2297–2309.
86. Zhang Z, Leir S-H, Harris A. Oxidative stress regulates CFTR gene expression in human airway epithelial cells through a distal antioxidant response element. Am J Respir Cell Mol Biol. 2015;52:387–396.
87. McKiernan PJ, Greene CM. MicroRNA dysregulation in cystic fibrosis. Mediators Inflamm. 2015;2015:529642.
88. Ezzie ME, Crawford M, Cho J-H, et al. Gene expression networks in COPD: microRNA and mRNA regulation. Thorax. 2012;67:122–131.
89. Savitski AN, Mesaros C, Blair IA, et al. Secondhand smoke inhibits both Cl- and K+ conductances in normal human bronchial epithelial cells. Respir Res. 2009;10:120.
90. Lambert JA, Raju SV, Tang LP, et al. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis. Am J Respir Cell Mol Biol. 2014;50:549–558.
91. Tyrrell J, Qian X, Freire J, et al. Roflumilast combined with adenosine increases mucosal hydration in human airway epithelial cultures after cigarette smoke exposure. Am J Physiol Lung Cell Mol Physiol. 2015;308:L1068–L1077.
92. Schmid A, Baumlin N, Ivonnet P, et al. Roflumilast partially reverses smoke-induced mucociliary dysfunction. Respir Res. 2015;16:135.
93. Dekkers JF, Van Der Ent CK, Beekman JM. Novel opportunities for CFTR-targeting drug development using organoids. Rare Dis. 2013;1:e27112.
94. Dekkers JF, Wiegerinck CL, De Jonge HR, et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med. 2013;19:939–945.
95. Okiyoneda T, Veit G, Dekkers JF, et al. Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nat Chem Biol. 2013;9:444–454.
96. Schwank G, Koo B-K, Sasselli V, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell. 2013;13:653–658.
97. Beekman JM. Individualized medicine using intestinal responses to CFTR potentiators and correctors. Pediatr Pulmonol. 2016;51:S23–S34.
98. Dekkers JF, Gogorza Gondra RA, Kruisselbrink E, et al. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids. Eur Respir J. 2016;48:451–458.
99. Dekkers R, Vijftigschild LAW, Vonk AM, et al. A bioassay using intestinal organoids to measure CFTR modulators in human plasma. J Cyst Fibros. 2015;14:178–181.
100. Noordhoek J, Gulmans V, Van Der Ent K, et al. Intestinal organoids and personalized medicine in cystic fibrosis. Curr Opin Pulm Med. 2016;22:610–616.
101. Zomer-Van Ommen DD, Vijftigschild LAW, Kruisselbrink E, et al. Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids. J Cyst Fibros. 2016;15:158–162.
102. Guimbellot JS, Leach JM, Chaudhry IG, et al. Nasospheroids permit measurements of CFTR-dependent fluid transport. JCI Insight. 2017;2(22).
103. Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol. 2008;26:1276–1284.
104. Haase A, Olmer R, Schwanke K, et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell. 2009;5:434–441.
105. Lachmann N, Happle C, Ackermann M, et al. Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2013;189:131126070906004.
106. Katsirntaki K, Mauritz C, Olmer R, et al. Bronchoalveolar sublineage specification of pluripotent stem cells: effect of dexamethasone plus cAMP-elevating agents and keratinocyte growth factor. Tissue Eng Part A. 2015;21:669–682.
107. Huang SXL, Islam MN, O’Neill J, et al. Efficient generation of lung and airway epithelial cells from human pluripotent stem cells. Nat Biotechnol. 2014;32:84–91.
108. Schmeckebier S, Mauritz C, Katsirntaki K, et al. Keratinocyte growth factor and dexamethasone plus elevated cAMP levels synergistically support pluripotent stem cell differentiation into alveolar epithelial type II cells. Tissue Eng Part A. 2013;19:938–951.